Apelin-induced cardioprotection against ischaemia/reperfusion injury: roles of epidermal growth factor and Src

Autor: Pasquale Pagliaro, Raffaella Rastaldo, Lisa Accomasso, Anna Folino, Gianni Losano, Claudia Giachino, Pier Giorgio Montarolo
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Male
Transcriptional Activation
medicine.medical_specialty
Cardiotonic Agents
Physiology
contracture
Myocardial Reperfusion Injury
030204 cardiovascular system & hematology
contractility
03 medical and health sciences
Transactivation
0302 clinical medicine
Epidermal growth factor
Internal medicine
medicine
PTEN
Animals
Rats
Wistar

PI3K/AKT/mTOR pathway
Cardioprotection
biology
Epidermal Growth Factor
Chemistry
PTEN Phosphohydrolase
Apelin
Rats
contractility
contracture
epidermal growth factor receptortransactivation
infa rct size
metalloproteinase
reperfusion injury salvagekinases pathway

030104 developmental biology
Endocrinology
src-Family Kinases
Cancer research
biology.protein
Phosphorylation
epidermal growth factor receptortransactivation
infa rct size
metalloproteinase
Proto-oncogene tyrosine-protein kinase Src
Signal Transduction
reperfusion injury salvagekinases pathway
Popis: Aim Apelin, the ligand of the G-protein-coupled receptor (GPCR) APJ, exerts a post-conditioning-like protection against ischaemia/reperfusion injury through activation of PI3K-Akt-NO signalling. The pathway connecting APJ to PI3K is still unknown. As other GPCR ligands act through transactivation of epidermal growth factor receptor (EGFR) via a matrix metalloproteinase (MMP) or Src kinase, we investigated whether EGFR transactivation is involved in the following three features of apelin-induced cardioprotection: limitation of infarct size, suppression of contracture and improvement of post-ischaemic contractile recovery. Method Isolated rat hearts underwent 30 min of global ischaemia and 2 h of reperfusion. Apelin (0.5 μm) was infused during the first 20 min of reperfusion. EGFR, MMP or Src was inhibited to study the pathway connecting APJ to PI3K. Key components of RISK pathway, namely PI3K, guanylyl cyclase or mitochondrial K+-ATP channels, were also inhibited. Apelin-induced EGFR and phosphatase and tensing homolog (PTEN) phosphorylation were assessed. Left ventricular pressure and infarct size were measured. Results Apelin-induced reductions in infarct size and myocardial contracture were prevented by the inhibition of EGFR, Src, MMP or RISK pathway. The involvement of EGFR was confirmed by its phosphorylation. However, neither direct EGFR nor MMP inhibition affected apelin-induced improvement of early post-ischaemic contractile recovery, which was suppressed by Src and RISK inhibitors only. Apelin also increased PTEN phosphorylation, which was removed by Src inhibition. Conclusion While EGFR and MMP limit infarct size and contracture, Src or RISK pathway inhibition suppresses the three features of cardioprotection. Src does not only transactivate EGFR, but also inhibits PTEN by phosphorylation thus playing a crucial role in apelin-induced cardioprotection.
Databáze: OpenAIRE